Skip to main content
OpenTrials
Completed

NCT Number: NCT03188263

Morning Light Treatment to Improve Glucose Metabolism

The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this project will be used to develop a larger clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States

About this study

This is a pilot study to determine whether light treatment can improve glucose metabolism in people with prediabetes. Individuals will be asked to complete a baseline session with one-week of at-home sleep monitoring followed by a 24-hour stay in the clinical research unit. During this stay, we will sample saliva in the evening to measure melatonin to estimate the timing of the internal biological clock ("circadian phase") and then we will perform a 3-hour oral glucose tolerance test in the morning to estimate markers of glucose metabolism, including insulin sensitivity. The participants will then be given a light device and instructed on its use. They will use the device for four weeks and visit our laboratory every week for a check-in. At the end of the four weeks, they will repeat the 24-hour stay in the clinical research unit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

34 subjects (50% female, age 40-65 y)

Subjects will be:

  • Prediabetic (HbA1c 5.7% to <6.5%)
  • overweight or obese (BMI>25 kg/m2)
  • be free of moderate to severe obstructive sleep apnea (apnea-hypopnea index<30).

The laboratory sessions will occur during women's follicular phase or women will be postmenopausal (≥6 months since last menses).

Subjects will be scheduled to participate ≥ 1 month from travel outside the central time zone, and during a time with minimal special events.

Exclusion criteria

  • Women who are pregnant, planning on becoming pregnant, or are breastfeeding.
  • Women on oral contraceptives or hormone replacement therapy will be excluded (alters OGTT and melatonin).
  • Men and women who have a child at home that does not sleep through the night will be excluded.
  • Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, and prisoners are also excluded.
  • History of any form of diabetes, including use of diabetes medications
  • Age outside 35-70 years (we will not enroll anyone older than 70 years because of a reduced response to light).
  • Smokers
  • Shift workers
  • Failed urine drug test (drugs of abuse, nicotine)
  • Eye disease/photosensitizing medications
  • Sleep medications, diagnosed sleep disorders (history of treatment may affect glucose metabolism),
  • Daily beta-blocker, NSAID or melatonin use (confounds DLMO)
  • History of psychiatric disorders (confounds effect of light treatment, per relevant items from Mood Disorder, Psychotic Screening and Substance Use Disorders Modules of the Structured Clinical Interview for DSM-IV Axis I Disorders - Non-Patient Edition (SCID-IV/NP) to screen for schizophrenia, bipolar depression, substance abuse, suicidal ideation, obsessive compulsive disorder, PTSD), depressive symptoms using the Center for Epidemiologic Studies - Depression (CES-D) scale
  • Irregular menses
  • History of cardiovascular disease (excluding hypertension), endocrine, kidney, gastrointestinal or liver disorder, seizures, and cancer.

Treatment and study plan

bright light

Other

1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.

Dim Light

Other

1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux

Primary outcomes

  1. Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT)

    Time frame: Change from baseline to after 4 weeks of light treatment

    The OGTT is a 3-hour procedure measuring blood glucose levels after the patient has consumed a 75-gram dextrose solution at -15 min, 0 min, 30 min, 60 min, 90 min, 120 min, and 180 min intervals. Total area-under-the-curve of glucose levels is calculated.

Secondary outcomes

  1. Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO)

    Time frame: Change from baseline to after 4 weeks of light treatment.

    The DLMO is measured via saliva samples collected during laboratory sessions. A sample is collected every half hour until bedtime starting 6.5 hours before habitual bedtime, and conducted in dim light setting to identify the point when melatonin starts being released.

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • Rush University

Registry information

Official study title

Morning Light Treatment at Home to Improve Glucose Metabolism in People at Increased Risk for Type 2 Diabetes

Acronym: ML

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jun 15, 2017
Registry last updated
Jan 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.